Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

o a contemporaneous control of PEGINTRON, full-dose REBETOL and boceprevir for 48 weeks. The primary endpoint of the study was SVR after 24 weeks of follow up. In the study, the 28-week and 48-week boceprevir no lead-in arms had SVR rates of 54 percent (n=58/107) and 67 percent (n=69/103), respectively.

The HCV SPRINT-1 study was conducted at sites across the United States, Canada and Europe. Overall, 77 percent of the 595 patients in the study were enrolled in the United States. African-Americans represented 16 percent of the patients enrolled and 7 percent of the patients in the study were cirrhotic.

Rationale for Lead-In Regimen

The use of the P/R lead-in prior to the addition of boceprevir was shown in the HCV SPRINT-1 study to reduce the incidence of viral breakthrough regardless of treatment duration. The rationale for the lead-in treatment regimen is based on the fact that both PEGINTRON and REBETOL reach steady-state concentrations by week 4, therefore patients have the protease inhibitor added at a time when the backbone drug levels have been optimized and viral load (HCV RNA) has been reduced. In addition, the patient's immune system will have been activated and primed by PEGINTRON at the time that boceprevir is added to the regimen. This approach may minimize the period of time when there is a "functional monotherapy" with a direct antiviral agent, potentially reducing the likelihood for the development of resistance.

About Ongoing Boceprevir Phase III Registration Studies

Patient enrollment has been completed in two ongoing randomized, double-blind, placebo-controlled registration studies evaluating boceprevir in combination with PEGINTRON and REBETOL compared to standard of care with PEGINTRON and REBETOL alone. More than 1,500 patients were enrolled in these studies at U.S. and international sites.

The HCV SPRINT-2 study evaluates the effi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  Invivotek L.L.C., ... is pleased to announce that its animal research ... for the Assessment and Accreditation of Laboratory Animal ... of animals in science worldwide through voluntary accreditation ... for animal care and use in 38 countries. ...
(Date:7/14/2014)... , July 14, 2014  Today, ATS Labs, ... that it acquired the assets of MicroTest Labs, Inc. ... acquisition of MTL is the first step in the ... laboratory services platform to support the medical device and ... as Accuratus Lab Services , a name that ...
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8
(Date:7/14/2014)... Last month Bromell Agency officially launched the ... features more detailed information on how clients can protect ... and boats in the state of Louisiana. , The ... the website in order to better educate clients on ... of the website, which is to display comprehensive insurance ...
(Date:7/14/2014)... Academy, senescent is he who "begins to age". But ... is senescence not a synonym of ageing, it is ... is such a badly named physiological process that those ... another name. That is the case of Manuel Serrano, ... of the world,s leading experts on senescence, who has ...
(Date:7/14/2014)... 2014 Physical fitness may buffer some of the adverse ... new study by researchers from the American Cancer Society, ... study appears in the journal Mayo Clinic Proceeding ... and obesity and blood markers associated with cardiovascular disease ... , Sedentary behavior has been linked to an increase ...
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
(Date:7/14/2014)... -- Being physically active in middle age appears to ... types of dementia, suggest the findings from two new ... exercise at various levels, especially in midlife, is beneficial ... Clinic, said in an Alzheimer,s Association news release. ... conclusive. More research is needed to determine the extent ...
Breaking Medicine News(10 mins):Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Staying Active May Help Prevent Dementia 2
... Food and Drug Administration,s (FDA) recent decision to approve ... treatment of non-Hodgkin,s lymphoma (NHL). "This is ... M. Graham, M.D., Ph.D., president of SNM and director ... College of Medicine. "We,ve known for some time that ...
... , ... superstore has beaten the thirty cents per card - three day production threshold on quantities ... Fort ... so few plastic cards so fast and at this price level. This is a special ...
... , , Members Take to ... with Constituent Health Care Stories to Congress , ... health care reform speech, and with Congress back to work in Washington, AARP ... what,s broken and preserve what,s right. , , ...
... , BELGRADE, Serbia, Sept. 10 /PRNewswire-FirstCall/ - HTDS ... its operating subsidiary Slavica Bio Chem www.slavicabiochem.com ... , , The equipment is ... http://www.expressionproteomics.com/LifeScience/pdf/Bulletin_3095.pdf , , , Dr.Ivana Gadjanski HTDS ...
... TEANECK, N.J., Sept. 10 After an 8 day trial, ... on September 4, 2009 by the Superior Court of New Jersey ... breaching her duty of loyalty. , , ... 2009, Ellen Koblitz, Presiding Judge of the Superior Court of New ...
... WALTHAM, Mass., Sept. 10 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger of ... several healthcare industry investor conferences during the month of September. , ... Chief Executive Officer, and Jon Russell, Vice President, Finance, will attend ...
Cached Medicine News:Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:My1Stop.com Offers Plastic Card Printing Promotion Beats the Thirty Cents per Card Threshold - Offering 1000 Cards in Only Three Days for $299 2Health News:AARP Delivers Health Care Reform 'Message in a Bottle' in Chicago 2Health News:Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects 2Health News:Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects 3Health News:Inverness Medical Innovations Announces September Investor Conference Schedule 2
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: